Italia markets close in 3 hours 18 minutes

Celyad Oncology SA (0QFK.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,5960-0,2060 (-11,43%)
Al 11:29AM BST. Mercato aperto.
Schermo intero
Chiusura precedente1,8020
Aperto1,5960
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno1,5960 - 1,5960
Intervallo di 52 settimane1,5960 - 1,5960
Volume79
Media VolumeN/D
Capitalizzazione193.471
Beta (5 anni mensile)1,11
Rapporto PE (ttm)N/D
EPS (ttm)-1,4420
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

    GOSSELIES, Belgium and MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufa

  • GlobeNewswire

    Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

    Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibitory-molecule (TIM)-based allogeneic CAR T candidate CYAD-101 for metastatic colorectal cancer (mCRC)Company to increase strategic focus on collaborations related to broad intellectual property portfolioConference call and

  • GlobeNewswire

    Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

    MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria for the trial. “We are pleased that the FDA